History of Longevity
For centuries, human beings have chased the dream of extending their life with a variety of products, often totally unrealistic.
Now however and especially in the past 5 years, scientific advances have made this a reality. Breakthroughs in biotech have transformed the quest for a longer, healthier life into real science.
Our company is leading this revolution, using cutting-edge technology to extend lifespans and enhance quality of life.
History of Longevity
For centuries, human beings have chased the dream of extending their life with a variety of products, often totally unrealistic.
Now however and especially in the past 5 years, scientific advances have made this a reality. Breakthroughs in biotech have transformed the quest for a longer, healthier life into real science.
Our company is leading this revolution, using cutting-edge technology to extend lifespans and enhance quality of life.
Visionaries Move into Longevity
The biotech sector is attracting global visionaries like Elon Musk and Jeff Bezos, who see its potential to reshape humanity’s future.
Inspired by this momentum, our team of top scientists, seasoned entrepreneurs, and influential advisors is pushing the boundaries of what’s possible in longevity.
Visionaries Move into Longevity
The biotech sector is attracting global visionaries like Elon Musk and Jeff Bezos, who see its potential to reshape humanity’s future.
Inspired by this momentum, our team of top scientists, seasoned entrepreneurs, and influential advisors is pushing the boundaries of what’s possible in longevity.
Radical Improvement
ALS (Amyotrophic Lateral Sclerosis) and glioblastoma once deemed incurable, have left patients with little hope.
However, we are now witnessing groundbreaking research, turning the tide, offering real advancements and new optimism for treatment.
Radical Improvement
ALS (Amyotrophic Lateral Sclerosis) and glioblastoma once deemed incurable, have left patients with little hope.
However, we are now witnessing groundbreaking research, turning the tide, offering real advancements and new optimism for treatment.
Now More Centennials in the World
The world is seeing a surge in centenarians, thanks to advances in healthcare and lifestyle.
Our mission is to ensure that longer life means better health, vitality, and independence.
We focus on adding quality to those extra years, empowering people to live longer, healthier, and more fulfilling lives.
Achieving 5555
Why 5555? The human brain is incredibly adaptable, and with the success of medical cannabis and breakthroughs in neurotherapies, we believe more people will reach lifespans of 5555 weeks – around 106 years.
Many people in G20 nations are on the path to significantly longer life expectancies. We’ve moved past common ailments like cataracts, joint replacements, and even many cardiac issues are now well-managed.
It’s already common to see leaders and public figures thriving well into their 80s and 90s. In addition, diseases like ALS (Amyotrophic Lateral Sclerosis) are being treated with remarkable new therapies, extending patients’ lifespans significantly.
Longevity Life Research, leveraging a proprietary formula from our parent company Andromeda LS Holdings Ltd, has developed a cutting-edge, patent-pending formulation enhanced with mycelium components. Led by Dr. Black, this innovation is poised to yield multiple formulations. Initial safety trials have been successfully completed.
Advancing Longevity
Longevity Revolution: In October 2019, the United Nations called this the start of a “longevity revolution” driven by aging boomers and medical breakthroughs.
Intergenerational connection: Never before in human history have so many generations been alive at the same time.
Future Outlook: Stanford predicts half of today’s 5-year-olds will reach 100.
100 is the New 80
By 2050, there will be an estimated 3.7 million centenarians globally, with Japan leading the way in longevity.
While this is a point of pride, Japan’s aging population and declining birthrates are triggering economic challenges.
Countries worldwide face similar issues as they plan for an increasingly elderly population.
Life Expectancy
The world has an estimated 722,000 centenarians and according to the United Nations’ population projections for 2054, this is expected to be 4 million.
The United Nations projects the number in the U.S. to be 108,000 centenarians, growing to 513,000 by 2054. Japan boasts the highest per capita, with 0.06% of its population aged 100+ and is also home to Kane Tanaka, the world’s oldest woman at 117.
100 is the New 80
By 2050, there will be an estimated 3.7 million centenarians globally, with Japan leading the way in longevity.
While this is a point of pride, Japan’s aging population and declining birthrates are triggering economic challenges.
Countries worldwide face similar issues as they plan for an increasingly elderly population.
Life Expectancy
The world has an estimated 722,000 centenarians and according to the United Nations’ population projections for 2054, this is expected to be 4 million.
The United Nations projects the number in the U.S. to be 108,000 centenarians, growing to 513,000 by 2054. Japan boasts the highest per capita, with 0.06% of its population aged 100+ and is also home to Kane Tanaka, the world’s oldest woman at 117.
The Economist Cover
Advances in longevity research are transforming the science of aging, making the prospect of living to 120 realistic.
While centenarians are currently just 0.03% of the population in the U.S. and U.K., living to 100 could soon be the norm, with 120 as an attainable goal.
Our focus isn’t just on extending life, but on enhancing healthy, vital years by addressing the biological roots of aging.
The Economist Cover
Advances in longevity research are transforming the science of aging, making the prospect of living to 120 realistic.
While centenarians are currently just 0.03% of the population in the U.S. and U.K., living to 100 could soon be the norm, with 120 as an attainable goal.
Our focus isn’t just on extending life, but on enhancing healthy, vital years by addressing the biological roots of aging.
DER SPIEGEL Cover
Global research hubs (Johns Hopkins, Harvard, Stanford, etc.) and major companies are racing to unlock the secrets of longer, healthier lives.
Lifestyle choices; diet, exercise, sleep, and brain health, can extend healthy life by decades. Regular exercise adds 2-8 years of life expectancy and
reduces risks of major diseases.
Aging can’t be fully stopped, but risks of diseases like
cancer and Alzheimer’s can be significantly reduced.
The Science & Our Formulation...
The main theory of aging has for over 60 years been that ‘oxidative stress’, from abnormal byproducts of metabolism called ‘free radicals’, damages large molecules such as proteins, lipids and DNA. The theory has been progressively validated.
The damage occurs by several mechanisms, especially by a low level of chronic inflammation. For example, markers of oxidative stress have been associated with low cognitive performance in elderly patients, as well as with markers of inflammation.
So a potential treatment to mitigate the limitations associated with our increasing lifespan would involve a treatment that combines anti-oxidant and anti-inflammatory properties that is well tolerated over the long term.
Our sister company, Andromeda LS Holdings Ltd holds a number of patents for a safe and non-psychoactive cannabinoid solution (i.e. no THC content) designed to treat various ailments, notably Long Covid. The components of our product are known to have anti-inflammatory effects.
At Longevity Life Research we have created a novel product using mycelium based compounds with known anti-oxidant properties to further enhance the excellent results already seen with our existing formulation.
Our goal is to optimise the quality of our longer lifespans by enhancing our cognitive and physical health
...Resulting in Our Credible Product
*GOVERNMENT APPROVAL PENDING*
We have successfully completed safety trials,
with pleasing data concerning stability and shelf life.
The product is already in use by 20 patients.
The product will be launched in early Q1 2025,
targeting an initial core distribution area.
This area will include Switzerland, southern Germany
(Bavaria and Baden-Württemberg), and Austria.
We’re currently waiting on relevant trademark and service mark registrations.
Management Board
Dr. med. Gottfried H. Sodeck
Chairman of the Board
Gottfried is an Assistant professor of Internal Medicine, entrepreneur, and biotech leader. With over a decade of experience as President and Managing Director of VOGELBUSCH, he has led global engineering and EPC projects in the pharma and biotech sectors, securing contracts worth over $750M.
Licensed to practice medicine in EMEA and the UK, Gottfried is fluent in German, English, and French. Based in Vienna, Austria, he balances his career with family life, alongside his wife and two children.
Dr. med. Gottfried H. Sodeck
Chairman of the Board
Gottfried is an Assistant professor of Internal Medicine, entrepreneur, and biotech leader. With over a decade of experience as President and Managing Director of VOGELBUSCH, he has led global engineering and EPC projects in the pharma and biotech sectors, securing contracts worth over $750M.
Licensed to practice medicine in EMEA and the UK, Gottfried is fluent in German, English, and French. Based in Vienna, Austria, he balances his career with family life, alongside his wife and two children.
Dr. H. Peter Black, MD
Chief Medical Officer
Dr. Black, MD CM, is a McGill-trained physician with a background in radiology and neurology. He co-founded a biotech company in 1994 that later went public and has held numerous board positions, including at AbitibiBowater and Nymox Corporation.
With leadership roles in biotech and finance, he has also served on cultural boards like the Montreal Symphony Orchestra and Washington Opera, and advises Johns Hopkins University.
Dr. H. Peter Black, MD
Chief Medical Officer
Dr. Black, MD CM, is a McGill-trained physician with a background in radiology and neurology. He co-founded a biotech company in 1994 that later went public and has held numerous board positions, including at AbitibiBowater and Nymox Corporation.
With leadership roles in biotech and finance, he has also served on cultural boards like the Montreal Symphony Orchestra and Washington Opera, and advises Johns Hopkins University.
Steven Splinter, PhD
Chief Scientist (Non-Medical)
Steven, Ph.D. in Engineering Science (1994),is an expert in interfacial phenomena with numerous publications and patents.He received the 5NR Science Award in 2003 for his work on MAP™ extraction technology.
As the founding president of Radient, he led the company for many years. Before that, he directed Chemical & Environmental Processes at BC Research, building a team focused on chemical and biochemical process development.
Steven Splinter, PhD
Chief Scientist (Non-Medical)
Steven, Ph.D. in Engineering Science (1994),is an expert in interfacial phenomena with numerous publications and patents.He received the 5NR Science Award in 2003 for his work on MAP™ extraction technology.
As the founding president of Radient, he led the company for many years. Before that, he directed Chemical & Environmental Processes at BC Research, building a team focused on chemical and biochemical process development.
Seema Gupta
Board Member
Seema brings 25+ years of business development and finance expertise, with a strong focus on the UK healthcare sector.
Holding a Diploma in Practice Management (AMSPAR) and a Bachelor’s from the University of Lucknow, she has launched successful ventures, served as Sales Director in construction since 2016, and held key finance roles at DMC Healthcare from 2002 to 2011.
Seema Gupta
Board Member
Seema brings 25+ years of business development and finance expertise, with a strong focus on the UK healthcare sector.
Holding a Diploma in Practice Management (AMSPAR) and a Bachelor’s from the University of Lucknow, she has launched successful ventures, served as Sales Director in construction since 2016, and held key finance roles at DMC Healthcare from 2002 to 2011.
Kassem Sobh
Board Member
Kassem Sobh, born to Lebanese parents in Jeddah, Saudi Arabia, moved to Montreal for his studies, earning degrees in Biochemistry and Computer Science from McGill and Concordia.After a successful stint in finance, focusing on high-net-worth clients, he transitioned to tech. Currently, Kassem is a senior leader at Insurity, a top cloud-based insurance software provider in North America.
Kassem Sobh
Board Member
Kassem Sobh, born to Lebanese parents in Jeddah, Saudi Arabia, moved to Montreal for his studies, earning degrees in Biochemistry and Computer Science from McGill and Concordia.
After a successful stint in finance, focusing on high-net-worth clients, he transitioned to tech. Currently, Kassem is a senior leader at Insurity, a top cloud-based insurance software provider in North America.
Adrian Marshal
Board Member
Adrian Marshall, former CEO of Nicoventures, led the creation of VOKET™, the first nicotine inhaler licensed as a safer smoking alternative. With 20+ years at BAT, he drove the ‘companys global ‘Harm Reduction’ and helped secure its place on the Dow Jones Sustainability Index.
After BAT, Adrian founded and sold a successful communications agency. He lives in Sussex, England.
Adrian Marshal
Board Member
Adrian Marshall, former CEO of Nicoventures, led the creation of VOKET™, the first nicotine inhaler licensed as a safer smoking alternative. With 20+ years at BAT, he drove the ‘companys global ‘Harm Reduction’ and helped secure its place on the Dow Jones Sustainability Index.
After BAT, Adrian founded and sold a successful communications agency. He lives in Sussex, England.
Team Members
Daz Baldwin
Dr. Gordon Balazsi MD
John Cronin
Cressida Rabela
COO
Scientific Advisory Panel Lead
Intellectual Property Collaborator
Government Relations/Medical
Team Members
Daz Baldwin
COO
Dr. Gordon Balazsi MD
Scientific Advisory Panel Lead
John Cronin
Intellectual Property Collaborator